PCRX — Pacira BioSciences, Inc.

PCRX closed at $36.39 (0.00%) on Oct 29, 2026. Float: 38.2M shares. Latest SEC filing: SC 14D9 on Oct 30, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for PCRX in the TickerWise workspace.

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Company profile

• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic
• Country: US
• Exchange: NASDAQ
• Employees: 788
• Website: https://www.pacira.com

Latest SEC filings for PCRX

• 2026-10-30SC 14D9
• 2026-08-07SCHEDULE 13G
• 2026-08-04S-8
• 2026-08-0410-Q
• 2026-08-048-K
• 2026-06-308-K
• 2026-06-133
• 2026-06-118-K
• 2026-04-3010-Q
• 2026-04-308-K

Latest PCRX news

• 2026-10-12Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX Read article
• 2026-10-11SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX) Read article
• 2026-10-09Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio Read article
• 2026-10-08Pacira BioSciences jumps 44% on Viatris acquisition deal Read article
• 2026-10-08SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX) Read article
• 2026-10-08Why Pacira BioSciences Skyrocketed Today Read article
• 2026-10-08PCRX Shareholder Alert: Ademi LLP Investigates Whether Buyout Fairly Values Pacira Biosciences, INC. Read article
• 2026-10-08PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders Read article

Related companies

• TAK — Takeda Pharmaceutical Company Limited
• ZTS — Zoetis Inc.
• TEVA — Teva Pharmaceutical Industries Limited
• HLN — Haleon plc
• VTRS — Viatris Inc.
• NBIX — Neurocrine Biosciences, Inc.
• RDY — Dr. Reddy's Laboratories Limited
• ELAN — Elanco Animal Health Incorporated

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.